Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network.
We analyzed antifungal susceptibilities of 274 clinical Aspergillus isolates from transplant recipients with proven or probable invasive aspergillosis collected as part of the Transplant-Associated Infection Surveillance Network (TRANSNET) and examined the relationship between MIC and mortality at 6 or 12 weeks. Antifungal susceptibility testing was performed by the Clinical and Laboratory Standards Institute (CLSI) M38-A2 broth dilution method for amphotericin B (AMB), itraconazole (ITR), voriconazole (VOR), posaconazole (POS), and ravuconazole (RAV). The isolate collection included 181 Aspergillus fumigatus, 28 Aspergillus niger, 27 Aspergillus flavus, 22 Aspergillus terreus, seven Aspergillus versicolor, five Aspergillus calidoustus, and two Aspergillus nidulans isolates and two isolates identified as Aspergillus spp. Triazole susceptibilities were < or = 4 microg/ml for most isolates (POS, 97.6%; ITR, 96.3%; VOR, 95.9%; RAV, 93.5%). The triazoles were not active against the five A. calidoustus isolates, for which MICs were > or = 4 microg/ml. AMB inhibited 93.3% of isolates at an MIC of < or = 1 microg/ml. The exception was A. terreus, for which 15 (68%) of 22 isolates had MICs of >1 microg/ml. One of 181 isolates of A. fumigatus showed resistance (MIC > or = 4 microg/ml) to two of three azoles tested. Although there appeared to be a correlation of higher VOR MICs with increased mortality at 6 weeks, the relationship was not statistically significant (R2 = 0.61; P = 0.065). Significant relationships of in vitro MIC to all-cause mortality at 6 and 12 weeks for VOR or AMB were not found.
Baddley
John W
JW
Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL 35294-0006, USA. jbaddley@uab.edu
Marr
Kieren A
KA
Andes
David R
DR
Walsh
Thomas J
TJ
Kauffman
Carol A
CA
Kontoyiannis
Dimitrios P
DP
Ito
James I
JI
Balajee
S Arunmozhi
SA
Pappas
Peter G
PG
Moser
Stephen A
SA
D000935:Antifungal Agents / Q000494:pharmacology*; D001228:Aspergillosis / Q000382:microbiology* / Q000401:mortality; D001230:Aspergillus / Q000187:drug effects* / Q000302:isolation & purification; D025141:Drug Resistance, Fungal; D006801:Humans; D016867:Immunocompromised Host; D008826:Microbial Sensitivity Tests; D014180:Transplantation / Q000009:adverse effects*
D000935:Antifungal Agents
J Antimicrob Chemother. 2008 Mar;61(3):616-20
18222957
Antimicrob Agents Chemother. 2002 Apr;46(4):1032-7
11897586
J Clin Microbiol. 2005 Oct;43(10):5243-6
16207990
Antimicrob Agents Chemother. 2008 Oct;52(10):3504-11
18644959
Clin Infect Dis. 2008 Feb 1;46(3):327-60
18177225
J Antimicrob Chemother. 1998 Oct;42(4):497-502
9818749
Stud Mycol. 2007;59:39-46
18490954
Int J Antimicrob Agents. 2006 Nov;28(5):450-3
17034993
N Engl J Med. 2002 Dec 26;347(26):2173-4
12501236
Antimicrob Agents Chemother. 1997 Jun;41(6):1364-8
9174200
PLoS Med. 2008 Nov 11;5(11):e219
18998768
J Clin Microbiol. 2004 Aug;42(8):3475-82
15297486
Eukaryot Cell. 2008 Apr;7(4):630-8
18281596
J Clin Microbiol. 2008 Aug;46(8):2568-72
18562581
Med Mycol. 2010 Feb;48(1):97-102
19296366
Antimicrob Agents Chemother. 2002 Feb;46(2):556-7
11796377
Pharmacotherapy. 2005 Sep;25(9):1174-80
16164392
Antimicrob Agents Chemother. 2008 Sep;52(9):3444-6
18606840
N Engl J Med. 2007 Apr 5;356(14):1481-3
17409336
J Infect Dis. 2003 Jul 15;188(2):305-19
12854088
Clin Infect Dis. 2008 Nov 1;47(9):1176-84
18808352
Clin Infect Dis. 2002 Jan 1;34(1):7-14
11731939
Antimicrob Agents Chemother. 2004 Sep;48(9):3217-25
15328076
Clin Microbiol Rev. 2001 Oct;14(4):643-58, table of contents
11585779
Antimicrob Agents Chemother. 2008 Jul;52(7):2468-72
18474574
J Infect. 2000 Nov;41(3):203-20
11120607
J Clin Microbiol. 2004 Jul;42(7):3137-41
15243072
Clin Infect Dis. 2007 Feb 15;44(4):531-40
17243056
Br J Haematol. 2005 Oct;131(2):201-7
16197450